Financial Schedules. Set forth in Section 2.13(a) of the Disclosure Letter are (i) unaudited selected results of operations data for each of the New Diamond Business (as defined in the Separation Agreement), the Standalone Drug Business and the Retained Business (as defined in the Separation Agreement) for the 52 weeks ended January 29, 2004, the 53 weeks ended February 3, 2005 and the 39 weeks ended November 3, 2005 (collectively, the “Separate Operations Data”) and (ii) unaudited selected balance sheet data for Albertson’s and each of Albertson’s operating regions as of February 3, 2005 ( the “Separate Balance Sheet Data”). The Separate Operations Data and the Separate Balance Sheet Data have been compiled from source books, records and financial reports of Albertson’s and its Subsidiaries. Such source books, records and financial reports were prepared by Albertson’s in the ordinary course of its business, are accurate in all material respects and were subject to Albertson’s internal controls. The allocations of the Separate Operations Data among the New Diamond Business, the Standalone Drug Business and the Retained Business are consistent with Section 2.13(a)(i) of the Disclosure Letter and the allocations of the Separate Balance Sheet Data are allocated in the manner described in Section 2.13(a)(ii) of the Disclosure Letter. The Separate Balance Sheet Data and the Separate Operations Data reconcile to Albertson’s historical financial statements filed with the SEC and, in Albertson’s opinion, present fairly, in all material respects, the information presented in the Separate Balance Sheet Data and the Separate Operations Data, respectively. Subject to the changes in accounting principles and methodologies effected by Albertson’s as described in the Company SEC Reports (as defined in the Merger Agreement), the accounting principles and methodologies used in the preparation of the Separate Operations Data were applied on a consistent basis, in all material respects, for each of the periods presented therein. Set forth in Section 2.13(a)(iii) of the Disclosure Letter are selected assets and liabilities included in the Purchased Assets and Assumed Liabilities, which schedule was prepared by Sellers and was compiled from source books, records and financial reports of Albertson’s and its Subsidiaries. Such source books, records and financial reports were prepared by Albertson’s in the ordinary course of its business, are accurate in all material respects and were subject to Albe...
Financial Schedules. 28 6.4 Business Since the Pacific and Southern Balance Sheet Date..................................................................28 6.5
Financial Schedules. 16 GAAP....................................................................... 10
Financial Schedules. Attached hereto as Schedule 2 are the audited balance sheet (including the accompanying notes) and related audited income statement as of and for the financial year ended December 31, 1996 for the Company (the "Financial Schedules"). The accounts included in the Financial Schedules present fairly and in all material respects the financial condition of the Company as of such date and the results of operations of the Company for such period.
Financial Schedules. 14 Freixxxxx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Financial Schedules. (a) A complete and correct listing of all of the Company's receivables as of February 28, 1997, is attached hereto as Schedule 2.7(a) (the "Receivables Schedule").
Financial Schedules. Set forth on Schedule 5.5 are selected unaudited prescription operations data (the “Rx Operations Data”) for each of the Operate Location Pharmacies, Existing Worksite Pharmacies and File-Transfer Locations, in each case, for the period commencing January 1, 2006 and ending November 25, 2006, and (ii) unaudited total revenues reports and certain unaudited balance sheet data (subject to purchase) and unaudited selling, general and administrative expenses for (w) each of the Operate Location Pharmacies, Existing Worksite Pharmacies and File-Transfer Locations, (x) Sellers’ pharmacies not being purchased by Buyer or Eastern, (y) Sellers’ corporate and administrative services, and (z) Sellers’ other businesses, including its internet business (collectively, the “Revenue, SG&A and Balance Sheet Data”), in each case as of (in the case of the balance sheet data) and for the period ended (in the case of the revenue and selling, general and administrative data) September 30, 2006 (the “Balance Sheet Date”). The Rx Operations Data and the Revenue, SG&A and Balance Sheet Data have been compiled from source books, records, pharmacy system and financial reports of FMRX and its Subsidiaries. The Rx Operations Data and the Revenue, SG&A and Balance Sheet Data fairly reflects in the aggregate, in all material respects, the prescription operating data, revenues and balance sheet data (subject to purchase), and the selling, general and administrative expenses, in each case, for the locations specified on Schedule 5.5 and for the periods set forth therein. The Sellers cost files for inventory at any date, and from time to time, reflect the actual costs of inventory that would be charged by McKesson or other applicable suppliers as of such date.
Financial Schedules. (i) Schedule 4(c) sets forth consolidated balance sheets of the Business as of, and the related consolidated statements of shareholder's equity, operations and cash flows for the Business for the fiscal years ended, October 2, 1993, October 1, 1994 and September 30, 1995 and the unaudited consolidated balance sheet of the Business as of, and related consolidated statements of shareholder's equity, operations and cash flows for the Business for the nine-month period ended, June 29, 1996 (in each case, prepared on a basis consistent with such audited statements and presented without separate footnotes), and a pro forma statement setting forth the Net Book Value as of June 29, 1996 (the "Initial Net Book Value Statement"), in each case together with the notes thereto (such schedules, together with the Initial Net Book Value Statement, being referred to herein as the "Financial Schedules"). The Financial Schedules have been derived from the accounting books and records of PHC and present fairly in all material respects the results of operations for the Business on the basis described in the notes thereto for the respective periods covered thereby and the statement of Net Book Value as of June 29, 1996 on the pro forma basis described in the notes thereto. The Financial Schedules have, in each case, been prepared in accordance with United States generally accepted accounting principles, consistently applied, except as otherwise provided on Schedule 2(b) or in the Financial Schedules (such accounting principles, together with the exceptions thereto, being referred to herein as the "Applicable Accounting Principles").
Financial Schedules. Set forth on Schedule 5.5 are selected unaudited prescription operations data (the “Operations Data”) for each of the Pharmacies, in each case, for the period commencing August 1, 2008 and ending on July 31, 2009. The Operations Data have been compiled from source books, records, pharmacy system and financial reports of Seller. The Operations Data fairly reflects in the aggregate, in all material respects, the prescription operating data, revenues and the selling, general and administrative expenses, in each case, for the locations specified on Schedule 5.5 and for the periods set forth therein.
Financial Schedules. Set forth on Schedule 6.8 are (a) the audited consolidated financial statements of Nyer as of June 30, 2008 and 2009, consisting of the balance sheet of Nyer as of June 30, 2008 and 2009 and the related statements of operations changes in shareholders’ equity and cash flows of Nyer for each of the years ended June 30, 2008 and 2009 (the “Financial Statements”); and (b) certain other selected financial information (the “Other Financial Data”). The Financial Statements and the Other Financial Data have been compiled from source books, records, pharmacy system and financial reports of Nyer. The Financial Statements and the Other Financial Data fairly reflects in the aggregate, in all material respects, the prescription operating data, revenues and the selling, general and administrative expenses, in each case, for the locations specified on Schedule 5.5 and for the periods set forth therein.
